Podcast Episodes
Back to Search
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patie…
2 years, 7 months ago
Deals, Dupixent and GLP-1 drug shortages
This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for …
2 years, 7 months ago
First ever CRISPR gene therapy approval: What happens next?
Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autotemce…
2 years, 7 months ago
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bi…
2 years, 7 months ago
Zepbound vs Wegovy: A two horse race
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioS…
2 years, 7 months ago
Q3 earnings recap: Winners, losers & surprises
This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's repo…
2 years, 8 months ago